Extensive liver metastasis of gastric cancer effectively treated by hepatic arterial infusion of 5-fluorouracil/cisplatin.

作者: Akio Moriya , Ichinosuke Hyodo , Tomohiro Nishina , Hiroya Imaoka , Atsushi Imagawa

DOI: 10.1007/PL00011695

关键词:

摘要: Most gastric cancer patients with jaundice caused by extensive liver metastasis show no tumor shrinkage response to systemic chemotherapy, while often showing severe adverse reactions. Their prognosis is very poor. We experienced two for whom hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU) and cisplatin through an implantable port was effective treating metastasis. One patient had (serum bilirubin level before HAI therapy, 12.4 mg/dl) metachronous metastasis, prior chemotherapy 5-FU irinotecan not been effective. The other synchronous also exhibited 11.8 mg/dl). Both were treated cisplatin, 20 mg/m(2) 30 min on day 1, continuous intraarterial 5-FU, 300 mg/m(2), from 1 4 every week. metastatic tumors significantly reduced in volume the disappeared. They survived 27 weeks, respectively. A pharmacokinetic study conducted during period partial remission revealed that extraction ratios 0.89 0.024, respectively, suggesting a favorable first-pass effect 5-FU. Although our findings here suggest successful local control could improve deteriorated condition prolong survival some far advanced cancer, it essential pay much attention possible effects treatment.

参考文章(16)
K A Campbell, R C Burns, J V Sitzmann, P A Lipsett, L B Grochow, J E Niederhuber, Regional chemotherapy devices: effect of experience and anatomy on complications. Journal of Clinical Oncology. ,vol. 11, pp. 822- 826 ,(1993) , 10.1200/JCO.1993.11.5.822
A Webb, D Cunningham, J H Scarffe, P Harper, A Norman, J K Joffe, M Hughes, J Mansi, M Findlay, A Hill, J Oates, M Nicolson, T Hickish, M O'Brien, T Iveson, M Watson, C Underhill, A Wardley, M Meehan, Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology. ,vol. 15, pp. 261- 267 ,(1997) , 10.1200/JCO.1997.15.1.261
Narikazu Boku, Atsushi Ohtsu, Yasuhiro Shimada, Kuniaki Shirao, Shigeki Seki, Hiroshi Saito, Yuh Sakata, Ichinosuke Hyodo, Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer Journal of Clinical Oncology. ,vol. 17, pp. 319- 323 ,(1999) , 10.1200/JCO.1999.17.1.319
Yasuaki Arai, Tokiko Endo, Yasuhiro Sone, Norihiro Tohyama, Yoshitaka Inaba, Satoru Kohno, Yutaka Ariyoshi, Choichiro Kido, Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system. Cancer Chemotherapy and Pharmacology. ,vol. 31, ,(1992) , 10.1007/BF00687116
Francois Geoffroy, Jean L. Grem, Chemotherapy of advanced gastrointestinal cancer Current Opinion in Oncology. ,vol. 6, pp. 427- 434 ,(1994) , 10.1097/00001622-199407000-00016
Yong-Suk Chung, Yoshito Yamashita, Tohru Inoue, Tasuku Matsuoka, Bunzo Nakata, Naoyoshi Onoda, Kiyoshi Maeda, Tetsuji Sawada, Yasuyuki Kato, Tetsuhiko Shirasaka, Michio Sowa, Continuous infusion of 5‐fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma Cancer. ,vol. 80, pp. 1- 7 ,(1997) , 10.1002/(SICI)1097-0142(19970701)80:1<1::AID-CNCR1>3.0.CO;2-#
Y Sakata, A Ohtsu, N Horikoshi, K Sugimachi, Y Mitachi, T Taguchi, Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients European Journal of Cancer. ,vol. 34, pp. 1715- 1720 ,(1998) , 10.1016/S0959-8049(98)00211-1
A. Ohtsu, Y. Shimada, S. Yoshida, H. Saito, S. Seki, K. Morise, M. Kurihara, Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG) European Journal of Cancer. ,vol. 30, pp. 2091- 2093 ,(1994) , 10.1016/0959-8049(94)00350-E
G. Milano, P. Roman, R. Khater, M. Frenay, N. Renee, M. Namer, Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. International Journal of Cancer. ,vol. 41, pp. 537- 541 ,(1988) , 10.1002/IJC.2910410411